Mineralys buys out lorundrostat royalties for $200M, secures $500M debt facility

Filed June 3, 2026 · Period ending June 2, 2026 · ~1 min read

Key Changes

• high

  MLYS paid Tanabe $200M upfront to eliminate all future royalty obligations on lorundrostat sales, converting to a royalty-free perpetual license while retaining up to $365M in commercial milestone payments.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• high

  Secured $500M term loan facility maturing June 2031: $100M drawn immediately, $150M Tranche B requires FDA approval by April 2027, and $250M in optional tranches tied to approval plus sales milestones.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• high

  If lorundrostat NDA is not approved by September 30, 2027, MLYS must repay all outstanding term loans in four equal quarterly installments starting that date.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →